EGFR-IN-139_product_DataBase

Bioactivity	EGFR-IN-139 (compound PD 18) is an epidermal growth factor receptor (EGFR) inhibitor, with IC50s of 12.88 (wild type), 10.84 (L858R/T790M), 42.68 (L858R/T790M/C797S) nM, respectively. EGFR-IN-139 displays strong anticancer activity against A549 and H1975 cancer cell lines, which are highly expressed EGFR. EGFR-IN-139 has a strong selectivity to cancer cells. EGFR-IN-139 can be used for nonsmall cell lung cancer (NSCLC) research[1].
Invitro	EGFR-IN-139 (1μM, 2 h) 抑制野生型 EGFR 和 L858R/T790M EGFR，抑制率分别为 90-100% 和 65-75%[1]。EGFR-IN-139 (0-100 μM, 72 h) 抑制 A549，H1975，Vero 细胞，其 IC50 分别为 28.23，29.46，180.9 μM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> EGFR-IN-139 相关抗体: Cell Proliferation Assay Cell Line:
CAS	1574321-31-5
Formula	C27H25ClN2O4
Molar Mass	476.95
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Todsaporn D, et al. Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR. J Phys Chem B. 2024 Dec 19;128(50):12389-12402.

PeptideDB